Year: 2021
Type: review
Abstract: Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, represents a major cause of morbidity and mortality in patients with cancer. Arterial thromboembolism, including myocardial infarction and stroke, is also prevalent. Risk differs in subgroups, with higher rates observed in specific cancers including pancreas, stomach, and multiple myeloma. Thromboprophylaxis is recommended for most patients with active cancer hospitalized for medical illnesses and after major cancer surgery. Outpatient thromboprophylaxis is not routinely recommended, but emerging data suggest that a high-risk population that benefits from pharmacological thromboprophylaxis can be identified using a validated risk tool. Direct oral anticoagulants are emerging as the preferred new option for the treatment of cancer-associated VTE, although low-molecular-weight heparin remains a standard for patients at high bleeding risk. Management of VTE beyond the first 6 months and challenging clinical situations including intracranial metastases and thrombocytopenia require careful management in balancing the benefits and risks of anticoagulation and remain major knowledge gaps in evidence.
Source: JACC CardioOncology
Authors: Lorenzo Gervaso, Heloni Dave, Alok A. Khorana
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Keywords: venous thromboembolism, arterial thromboembolism, cancer-associated thrombosis, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboprophylaxis, direct oral anticoagulants, low molecular weight heparin, anticoagulation management, brain metastases, thrombocytopenia, cancer risk stratification
Open Access status: gold
Estimated APC paid: $2,500
OpenAlex ID: W3155033451
